Elkayam Uri, Singh Harpreet, Irani Adil, Akhter Mohammed W
Division of Cardiovascular Medicine, Department of Medicine, University of Southern California, Keck School of Medicine, Los Angeles, California 90033, USA.
J Cardiovasc Pharmacol Ther. 2004 Jun;9(2):107-15. doi: 10.1177/107424840400900206.
Pregnancy is associated with an increased risk of thrombosis in women with mechanical prosthetic heart valves. Effective anticoagulation is therefore critical in such patients but remains problematic, since oral anticoagulation and both unfractionated and low-molecular-weight heparin may be associated with important fetal and maternal side effects.
To review information related to the use of anticoagulation with both warfarin and heparin and reassess the safety and efficacy of these therapies in pregnant women with mechanical prosthetic heart valves.
A MEDLINE search from 1966 to October 2003 for English and non-English language articles that reported the use of anticoagulation in pregnancy was conducted. Articles were included if they reported use of anticoagulation in pregnancy with emphasis on those that included women with mechanical prosthetic heart valves.
Anticoagulation prophylaxis with both warfarin and heparin (unfractionated heparin and low-molecular-weight heparin) may be associated with important fetal and maternal side effects. Optional regimens for the treatment of low-risk and high-risk patients are proposed to minimize potential complications.
对于患有机械人工心脏瓣膜的女性,妊娠会增加血栓形成风险。因此,有效的抗凝治疗对于此类患者至关重要,但仍存在问题,因为口服抗凝药以及普通肝素和低分子肝素都可能伴有严重的胎儿和母体副作用。
回顾与华法林和肝素抗凝治疗相关的信息,并重新评估这些疗法在患有机械人工心脏瓣膜的孕妇中的安全性和有效性。
对1966年至2003年10月期间发表的英文和非英文文章进行了MEDLINE检索,这些文章报道了妊娠期间的抗凝治疗使用情况。如果文章报道了妊娠期间的抗凝治疗使用情况,且重点关注了患有机械人工心脏瓣膜的女性,则将其纳入。
华法林和肝素(普通肝素和低分子肝素)的抗凝预防可能会伴有严重的胎儿和母体副作用。针对低风险和高风险患者提出了可选的治疗方案,以尽量减少潜在并发症。